KaydedilenlerDerginizi ekleyin

Dergiler / The Anatolian Journal of Cardiology / 2021 / Cilt: 25 - Sayı: 9

Sustained response to targeted therapies in a patient with pulmonary hypertension owing to Langerhans cell histiocytosis

Aykun HAKGÖR
Hacer Ceren TOKGÖZ
Özgür Yaşar AKBAL
Seda TANYERİ
Berhan KESKİN
Barkın KÜLTÜRSAYAR
Ali KARAGÖZ
Cihangir KAYMAZ
Sayfa
665–668
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Generally, pulmonary arterial hypertension (PAH) targeted therapies are not considered to be beneficial in this subgroup of PH.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Pulmonary hypertension (PH) in association with Pulmonary Langerhans Cell Histiocytosis (PLCH) is an uncommon pulmonary vascular disease classified in group 5 PH according to currently available guidelines for the diagnosis and treatment of PH.
📊
Temel Bulgular & Veri:Oxygen support, diuretic treatment and lung transplantation are standard therapies for this disease.
💡
Sonuç & Katkı:Generally, pulmonary arterial hypertension (PAH) targeted therapies are not considered to be beneficial in this subgroup of PH.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Pulmonary hypertension (PH) in association with Pulmonary Langerhans Cell Histiocytosis (PLCH) is an uncommon pulmonary vascular disease classified in group 5 PH according to currently available guidelines for the diagnosis and treatment of PH. Oxygen support, diuretic treatment and lung transplantation are standard therapies for this disease. Generally, pulmonary arterial hypertension (PAH) targeted therapies are not considered to be beneficial in this subgroup of PH.

🔖

Bu Makaleye Atıf Yap

HAKGÖR, A., TOKGÖZ, H. C., AKBAL, Ö. Y., TANYERİ, S., KESKİN, B., KÜLTÜRSAYAR, B., KARAGÖZ, A., KAYMAZ, C. (2021). Sustained response to targeted therapies in a patient with pulmonary hypertension owing to Langerhans cell histiocytosis. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 9, 665–668. https://ajindex.com/articles/365165

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Roden AC, Yi ES. Pulmonary Langerhans Cell Histiocytosis: An Update From the Pathologists' Perspective. Arch Pathol Lab Med 2016; 140: 230-40. [Crossref] 2. Kinoshita Y, Watanabe K, Sakamoto A, Hidaka K. Pulmonary Langerhans Cell Histiocytosis-associated Pulmonary Hypertension Showing a Drastic Improvement Following Smoking Cessation. Intern Med 2016; 55: 491-5. [Crossref] 3. Epaud R, Ducou Le Pointe H, Fasola S, Ploussard S, Delestrain C, Sileo C, et al. Cladribine improves lung cysts and pulmonary function in a child with histiocytosis. Eur Respir J 2015; 45: 831-3. [Crossref] 4. Nemoto K, Oh-Ishi S, Inui T, Nakazawa M, Hyodo K, Nakajima M, et al. Long-term improvement during tadalafil therapy in a patient with pulmonary hypertension secondary to pulmonary Langerhans cell histiocytosis. Respir Med Case Rep 2016; 18: 54-7. [Crossref] 5. May A, Kane G, Yi E, Frantz R, Vassallo R. Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. Respir Med Case Rep 2014; 14: 13-5. [Crossref] 6. Le Pavec J, Lorillon G, Jaïs X, Tcherakian C, Feuillet S, Dorfmüller P, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142: 1150-7. [Crossref] 7. Fartoukh M, Humbert M, Capron F, Maître S, Parent F, Le Gall C, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161: 216-23. [Crossref] 8. Yoshida T, Konno S, Tsujino I, Sato T, Ohira H, Chen F, et al. Severe pulmonary hypertension in adult pulmonary Langerhans cell histiocytosis: the effect of sildenafil as a bridge to lung transplantation. Intern Med 2014; 53: 1985-90. [Crossref] 9. Weatherald J, Savale L, Humbert M. Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications? Curr Hypertens Rep 2017; 19: 86. [Crossref]